Application of splenomegaly in determining treatment effect of immune checkpoint inhibitor of tumor patient

Abstract

The invention discloses an application of splenomegaly in determining the treatment effect of an immune checkpoint inhibitor of a tumor patient. According to the invention, the splenomegaly is found to be an independent prediction factor of the total lifetime of a primary liver cancer patient receiving the treatment of the immune checkpoint inhibitor for the first time; the curative effect, prognosis or total lifetime of a primary liver cancer patient treated by the immune checkpoint inhibitor can be predicted by utilizing the splenomegaly measured in iconography, certain clinical value is achieved, and the splenomegaly serving as a new immunotherapy predictive factor can promote precise medical treatment. Moreover, the judgment on the splenomegaly is simple and accurate, the method for evaluating whether the splenomegaly is combined with the patient or not through CT or MRI is simple, convenient and accurate clinically, and whether the patient has the splenomegaly or not is evaluated by selecting CT or MRI. When the maximum diameter of the spleen exceeds 15 cm, the patient is diagnosed as splenomegaly.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to the application of splenomegaly in determining the therapeutic effect of immune checkpoint inhibitors for tumor patients. Background technique [0002] Immune checkpoint inhibitors (ICIs), represented by programmed cell death protein-1 (PD-1) or programmed cell death ligand 1 (PD-L1) monoclonal antibodies, have changed the treatment paradigm, and immune checkpoint inhibition Drugs play an increasingly important role in the treatment of primary liver cancer Survival and progression-free survival were significantly prolonged. According to ASCO, the combination of atalizumab and bevacizumab has been recommended as a first-line drug for advanced liver cancer; Inducing durable immune responses per patient in the population of patients with aggressive HCC, even in the PD-L1-positive population, there is an urgent need for reliable immunotherapy predictors to facilitat...

AI Technical Summary

Problems solved by technology

Therefore, patients with splenomegaly may affect the efficacy of immune checkpoint inhibitors due to immune microenvironment dysregulation

There are not many clinical studies on liver cancer associated with splenomegaly, and no studies have reported the relationship between splenomegaly and overall survival in patients with primary liver cancer treated with immune checkpoint inhibitors

Images